9. Segment Reporting The Company determined its reporting units in accordance with ASC 280, Segment Reporting (ASC 280). The Company historically has reported its operating results as a single reportable segment described as the business of developing and commercializing a variety of products that support the detection, intervention and monitoring of a range of eye diseases. The Companys chief executive officer, who is the Chief Operating Decision Maker (CODM), has historically reviewed financial information on an aggregated basis for purposes of allocating resources and evaluating financial performance. In September 2017, the Company, through its wholly-owned subsidiary VectorVision Ocular Health, Inc., acquired substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specialized in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy study visual acuity testing. In August 2018, the Company created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (TDSI). The Company has established TDSI operations with selected clinics and is focusing on expanding its client base. In September 2019, the Companys newly-formed wholly-owned subsidiary, NutriGuard Formulations, Inc. (NGFI), completed an asset purchase agreement with NutriGuard Research, Inc., and NutriGuards sole shareholder, Mark McCarty. The Company intends to utilize the NGFI subsidiary to build a nutraceutical brand and product portfolio based on updated and reformulated compounds. The addition of potential new products or services as the Company grows requires management to periodically reevaluate its reporting structure. As sales of our medical foods as well as sales of VectorVision products grow, there is an increased need for the CODM to evaluate revenue and gross profit on a product line or group basis for purposes of resource allocation. As of March 31, 2020, the TDSI and NGFI subsidiaries do not meet the required quantitative criteria to be considered a reportable operating segment. Additionally, these subsidiaries do not share similar economic characteristics or a majority of the aggregation criteria set forth in ASC 280, and therefore are included in the category Corporate below. The TDSI and NGFI businesses earned $3,400 and $11,344 of service revenue, respectively, and incurred approximately $84,483 and $22,995 of operating costs, respectively, during the three months ended March 31, 2020. As of March 31, 2020, based on anticipated growth and the expanding diversity of product and service offerings by the Company, management has concluded that results should be reported in two segments: Medical Foods and Medical Devices. The following tables set forth our results of operations by segment (results allocated to Corporate consist of the TDSI and NGFI operations): For the Three Months Ended March 31, 2020 Corporate Medical Foods Medical Devices Total Revenue $ 14,744 $ 139,789 $ 91,190 $ 245,723 Cost of goods sold 2,270 66,196 40,642 109,108 Gross profit 12,474 73,593 50,548 136,615 Operating expenses 107,478 2,248,909 116,450 2,472,837 Loss from operations $ (95,004 ) $ (2,175,316 ) $ (65,902 ) $ (2,336,222 ) For the Three Months Ended March 31, 2019 Corporate Medical Foods Medical Devices Total Revenue $ - $ 99,934 $ 142,604 $ 242,538 Cost of goods sold - 38,272 55,220 93,492 Gross profit - 61,662 87,384 149,046 Operating expenses 48,763 1,076,744 205,032 1,330,539 Loss from operations $ (48,763 ) $ (1,015,082 ) $ (117,648 ) $ (1,181,493 ) The following tables set forth our total assets by segment. Intersegment balances and transactions have been removed: As of March 31, 2020 Corporate Medical Foods Medical Devices Total Current assets Cash $ 12,890,140 $ - $ - $ 12,890,140 Inventories 157,557 243,992 357,536 759,085 Other 266,663 340,849 46,530 654,042 Total current assets 13,314,360 584,841 404,066 14,303,267 Right of use asset, net - 476,187 58,543 534,730 Property and equipment, net - 247,205 136,281 383,486 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 13,314,360 $ 1,369,984 $ 598,890 $ 15,283,234 As of December 31, 2019 Corporate Medical Foods Medical Devices Total Current assets Cash $ 11,115,502 $ - $ - $ 11,115,502 Inventories 5,003 126,708 179,230 310,941 Other 7,399 219,223 214,653 441,275 Total current assets 11,127,904 345,931 393,883 11,867,718 Right of use asset - 509,464 63,250 572,714 Property and equipment, net - 219,056 155,582 374,638 Intangible assets, net - 50,000 - 50,000 Other - 11,751 - 11,751 Total assets $ 11,127,904 $ 1,136,202 $ 612,715 $ 12,876,821